AI Summary
Dr. Griffin provides a clinical update on respiratory syncytial virus, influenza, and SARS-CoV-2 statistics, discusses revised CDC guidelines for treating respiratory viral infections, effectiveness of SARS-CoV-2 vaccines, dispelling the myth of viral rebound, antiviral therapies, and diagnosing long COVID effects. He also covers ivermectin as an antiviral drug, the use of steroids and convalescent plasma, cognitive impacts of COVID-19, and healthcare challenges in diagnosing long COVID. The discussion includes various resources and guidelines for managing respiratory viruses and COVID-19.
In his weekly clinical update, Dr. Griffin reviews recent statistics on the circulation of respiratory syncytial virus, influenza and SARS-CoV-2 before discussing revised guidelines for how to treat respiratory viral infection guidelines by the CDC, effectiveness of the new SARS-CoV-2 vaccines and the combination of vaccination and antiviral therapy against the development of disease, continues to dispel the myth of viral rebound, how to pay for paxlovid, the lack of evidence supporting ivermectin as an antiviral drug, when to use steroids and the benefits of convalescent plasma, how COVID-19 affects cognitive function and the effect of long COVID and how healthcare works have difficulty making the proper diagnosis for long COVID even using a questionnaire.
Click arrow to play
Download TWiV 1094 (38 MB .mp3, 53 min)
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- Respiratory disease surveillance (CDC)
- RSV surveillance (CDC)
- RSV national trend (CDC)
- Influenza/flu surveillance (CDC)
- Influenza/flu map (CDC)
- COVID-19 hospital admissions (CDC)
- COVID-19 national trend (CDC)
- COVID-19 wastewater testing (biobot)
- Variant tracker (CDC)
- Variant hospital admissions (CDC)
- What to do when you are sick with a respiratory virus (CDC)
- Basis for respiratory virus guidance (CDC)
- Effectiveness of updated COVID-19 vaccines (MMWR)
- CDC Quarantine guidelines (CDC)
- NIH COVID-19 treatment guidelines (NIH)
- Synergy or additive protection with vaccination and oral antivirals (CID)
- To rebound or to not rebound (MMWR)
- Know your COVID-19 tools (ESMED)
- How to pay for Paxlovid (PAXCESS)
- Molnupiravir safety and efficacy (JMV)
- Still talking about Ivermectin? (Journal of Infection)
- Convalescent plasma recommendation for immunocompromised (IDSociety)
- Steroids,dexamethasone at the right time (OFID)
- Anticoagulation guidelines (hematology.org)
- Cognition and memory after COVID-19 (NEJM)
- Loss of IQ after SARS-CoV-2 infection (CIDRAP)
- Really, more evidence for long COVID and impaired cognition (NEJM)
- Memory assessment before and after COVID-19 (NEJM)
- Please complete this memory questionnaire (Community hyperbaric)
- Impact of long-term COVID-19 on workers in healthcare settings (PLoS One)
- Healthcare workers have difficulty assessing long COVID (CIDRAP)
- Contribute to our ASTMH fundraiser at PWB
- Letters read on TWiV 1094
- Dr. Griffin’s COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv
The post TWiV 1094: Clinical update with Dr. Daniel Griffin first appeared on This Week in Virology.